Abstract
The fact that newly discovered API’s (about 90%) or new molecular entity (NME) have little or poor aqueous solubility, causes a significant challenges to the initialization of development and commercialization of dosage form at the manufacturing facility. Poor aqueous solubility of API’s has critical role in drug dissolution or availability of drug at the site of actionor bioavailability, when a dosage form is administered orally. Various techniques are available for the enhancement of solubility but all individual techniques have its own limitations for commercialization. The known Solubility enhancement techniques like Solid dispersions involved the dispersion of poorly soluble drug in a suitable inert carrier at a molecular level and form amorphous and highly soluble compounds. The conversion of compound in to amorphous form or reduction of particle size to its molecular level caused enhanced solubility of poorly soluble by the application of solid dispersion techniques.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: International Journal of Pharma Professional’s Research (IJPPR)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.